



THE ORPHAN ONCOLOGY INNOVATOR

## ***Disclosure of total number of voting rights and number of shares in the capital at August 31, 2015***

**Paris, September 3, 2015** – Pursuant to article L.233-8 II of the *Code de commerce* (the French Commercial Code) and article 223-16 of the *Règlement général de l'Autorité des Marchés Financiers* (Regulation of the French stock market authority):

Date	Total number of outstanding shares	Total number of voting rights
August 31, 2015	40, 552, 083	Theoretical number of voting rights: 40, 552, 083 (including treasury shares)  Number of real voting rights: 40, 510, 182 (without treasury shares)

At August 31, 2015, the Company's capital stands at €10,138,020.75.

### **About Onxeo**

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to "make the difference". The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.

### **Key products at advanced development stage are:**

Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma

Validive® (Clonidine Lauriad®): Positive complete results of the Phase II trial in severe oral mucositis

Beleodaq® (belinostat): registered in the US in 2<sup>nd</sup> line treatment of peripheral T-cell lymphoma

For more information, visit the website [www.onxeo.com](http://www.onxeo.com)

### **Contacts :**

Judith Greciet, CEO  
[j.greciet@onxeo.com](mailto:j.greciet@onxeo.com)  
Nicolas Fellmann, CFO  
[n.fellmann@onxeo.com](mailto:n.fellmann@onxeo.com)  
+33 1 45 58 76 00

Caroline Carmagnol and Florence Portejoie  
[onxeo@alizerp.com](mailto:onxeo@alizerp.com)  
+33 6 64 18 99 59 / +33 1 44 54 36 66